Annual Meeting Schedule

Browse the 32nd Annual Meeting Schedule by day:

Friday, Nov. 10

7 – 8 a.m. Breakfast Maryland & Cherry Blossom Foyers
7 a.m. – 6:30 p.m. Registration Cherry Blossom Foyer

Session 100: National Cancer Institute Update

8 8:05 a.m. Presidential Welcome
Lisa H. Butterfield, PhD – University of Pittsburgh
Maryland Ballroom
8:05 8:20 a.m. National Cancer Institute Update
T. Kevin Howcroft, PhD National Cancer Institute
8:20 8:35 a.m. 2016 NCI Immunotherapy Fellowship Update
Julius Strauss, MD National Cancer Institute

Session 101: Keynote Address

8:35 8:40 a.m. Welcome and Introductions
Lisa H. Butterfield, PhD – University of Pittsburgh
Maryland Ballroom
8:40 9:20 a.m. The CAR T Revolution in Leukemia
Stephan Grupp, MD, PhD – University of Pennsylvania
9:20 9:25 a.m. Q&A and Closing Remarks
Stephan Grupp, MD, PhD – University of Pennsylvania

Session 102: Science Behind the Therapy: Mechanisms of Efficacy & Toxicity

Co-Chairs:

Kevan Herold, MD – Yale University
Arlene Sharpe, MD, PhD – Harvard Medical School

9:25 9:35 a.m. Introduction
Arlene Sharpe, MD, PhD Harvard Medical School
Maryland Ballroom
9:35  9:55 a.m. Clinical Overview of Checkpoint Inhibitors
Jeffrey A. Sosman, MD Northwestern University
9:55 10:15 a.m. Autoimmune Endocrinopathies
Kevan Herold, MD – Yale University
10:15  10:30 a.m. Break Maryland Foyer
10:30 10:50 a.m.

Colitis
Michael Dougan, MD, PhD – Massachusetts General Hospital

Maryland Ballroom

10:50  11:10 a.m. Cardiovascular Autoimmunity
Andrew Lichtman, MD, PhD Brigham and Women's Hospital
11:10  11:30 a.m. Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analyses of Patient, Protocol and Product Attributes
Mark J. Gilbert, MD Juno Therapeutics, Inc.
11:30 11:45 a.m. Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis
Jennifer Wu, PhD Northwestern University
11:45 a.m.  Noon Diversity and Composition of the Gut Microbiome Influences Responses to Anti-PD1-Therapy Through Beneficial Changes in Innate and Adaptive Immunity
Vancheswaran Gopalakrishnan, PhD The University of Texas MD Anderson Cancer Center

Session 103: Late-Breaking Abstract Session I

Noon  12:15 p.m. Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies
Thomas S. Uldrick, MD – National Cancer Institute
Maryland Ballroom
12:15 12:30 p.m. Nivolumab in Mismatch-Repair Deficient (MMR-d) Cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D Preliminary Results
Nilofer Azad, MD – Johns Hopkins University
12:30 2 p.m. Lunch & Poster Viewing/Presentations
Prince George Exhibition Hall DE
12:45 1:45 p.m. Oral Poster Presentations Back of Exhibition Hall DE

Concurrent Session 104: Clinical Trials: New Agents

Co-Chairs:
1:45 2 p.m.

First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
Robert Vonderheide, MD, PhD – Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania


Maryland Ballroom

2 – 2:15 p.m. First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies
Peter Ellmark, PhD – Alligator Bioscience
2:15 – 2:30 p.m. Monotherapy Dose Escalation Clinical and Translational Data from First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective, PI3K-Gamma Inhibitor Targeting Tumor Macrophages
David Hong, MD – University of Texas MD Anderson Cancer Center
2:30 – 2:45 p.m. Phase 1 Trial of CA-170, a First-in-Class, Orally Available, Small Molecule Immune Checkpoint Inhibitor (ICI) Dually Targeting PD-L1 and VISTA, in Patients with Advanced Solid Tumors or Lymphomas

Yung Jue Bang, PhD, MD – Seoul National University Hospital

2:45 3 p.m. Phase I trial of IL-15 Superagonist ALT-803 (IL-15N72D:IL-15RαSu/IgG1 Fc complex) in Advanced Solid Tumors: Tolerability and Correlates of Activity
Kim Margolin, MD, FACP – City of Hope
3 3:15 p.m. Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents
James L. Gulley, MD, PhD, FACP – National Cancer Institute
3:15 3:30 p.m. Phase I study of E7046, a Novel PGE2 Receptor Type 4 Inhibitor, in Patients with Advanced Solid Tumors with High Myeloid Infiltrate: Effects on Myeloid - and T-Lymphoid Cell-Mediated Immunosuppression
Aurelien Marabelle, MD, PhD – Gustave Roussy Institute

Concurrent Session 105: Building Personalized Vaccines and Technologies for Hematologic Malignancies and Solid Tumors

Co-Chairs:

Matthew M. Gubin, PhD – Washington University of Medicine
Catherine J. Wu, MD – Dana-Farber Cancer Institute

2 2:05 p.m. Introduction
Matthew M. Gubin, PhD – Washington University School of Medicine
Cherry Blossom Ballroom
2:05 2:25 p.m. Preclinical & Mouse Models
Matthew M. Gubin, PhD – Washington University School of Medicine
2:25 2:45 p.m. Tumor Vaccines in AML
David E. Avigan, MD – Beth Israel Deaconess Medical Center
2:45 3:05 p.m. Improvement in Epitope Discovery
Catherine J. Wu, MD – Dana-Farber Cancer Institute
3:05 3:20 p.m. Predictive Biomarkers for Response to Anti-CTLA-4 and Anti-PD-1 Immunotherapy in Melanoma Patients
Priyanka Subrahmanyam, PhD Stanford University

Session 106: High Impact Clinical Trial Results

Chair:

Mario Sznol, MD Yale School of Medicine

3:30 3:35 p.m. Introduction
Mario Sznol, MD – Yale School of Medicine
Maryland Ballroom
3:35 – 3:50 p.m. Pooled 3-Year Overall Survival Data from Phase II and Phase III Trials of Nivolumab (NIVO) Combined with Ipilimumab (IPI) in Advanced Melanoma
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
3:50 4:05 p.m. Nivolumab + Ipilimumab (N+I) vs Sunitinib (S) for Treatment-Naïve Advanced or Metastatic Renal Cell Carcinoma (aRCC): Results From CheckMate 214, including Overall Survival by Subgroups
Robert J. Motzer, MD – Memorial Sloan Kettering Cancer Center
4:05 4:20 p.m.
Immune and Tumor Responses to Human IL-10 (AM0010, Pegilodecakin) Alone or in Combination with Immune Checkpoint Blockade
Martin Oft, MD – ARMO BioScience
4:20 4:35 p.m. A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors
Glen J. Weiss, MD – Western Regional Medical Center Inc.
4:35 4:50 p.m. Expert Discussant
Samir Khleif, MD – Georgia Cancer Center
4:50 5:05 p.m. Break Prince George Exhibition Hall DE

Concurrent Session 107: Oncolytic Viruses and Intratumoral Therapies

Co-Chairs:

Howard L. Kaufman, MD, FACS Replimune Group, Inc.
Samuel Rabkin, PhD Massachusetts General Hospital 

5:05 5:10 p.m. Introduction
Howard L. Kaufman, MD, FACS – Replimune Group, Inc.
Cherry Blossom Ballroom
5:10 5:30 p.m. Oncolytic Viruses in Combination Immunotherapy Approaches
Howard L. Kaufman, MD, FACS – Replimune Group, Inc.
5:30 5:50 p.m. Oncolytic Herpes Simplex Virus Immunovirotherapy for Glioblastoma
Samuel Rabkin, PhD – Massachusetts General Hospital 
5:50 6:10 p.m. Oncolytic Virus Clinical Data
Brian D. Lichty, PhD – McMaster University
6:10 6:25 p.m. Preclinical Characterization of a Novel STING Agonist, MK-1454
Saso Cemerski, PhD Merck Research Laboratories
6:25 – 6:30 p.m. Closing Remarks
Samuel Rabkin, PhD – Massachusetts General Hospital

Concurrent Session 108: Energizing Immune Cell Metabolism in Cancer

Co-Chairs:
Nicholas P. Restifo, MD National Cancer Institute
Susan M. Kaech, PhD Yale University

5:05 – 5:25 p.m. Anti-Tumor T Cells: You Are What You Eat
Susan M. Kaech, PhD – Yale University
Maryland Ballroom
5:25 – 5:45 p.m. Metabolic Control of T Cell Epigenetics
Nicholas P. Restifo, MD – National Cancer Institute
5:45 – 6:05 p.m. Metabolic Changes in Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh
6:05 – 6:20 p.m. Re-Educating Macrophage through Glutamine Metabolism-Mediated Metabolic and Epigenetic Reprogramming
Ping-Chih Ho, PhD – University of Lausanne
6:20 – 6:35 p.m. Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment
McLane Watson, BS – University of Pittsburgh
6:30 – 8 p.m. Poster Reception Viewing and Presentations
Prince George Exhibition Hall DE
8 – 9 p.m. Presidential Reception & Membership Business Meeting Cherry Blossom Ballroom

Saturday, Nov. 11

7 – 8 a.m. Breakfast Maryland & Cherry Blossom Foyers
7 a.m. – 6:30 p.m. Registration Cherry Blossom Foyer
8:05 a.m. Organizer Welcome
Charles G. Drake, MD, PhD – Columbia University Medical Center
Maryland Ballroom

Session 200: Update Session - Cancer Immunotherapy Trials Network (CITN) Update

8:05 – 8:35 a.m. Cancer Immunotherapy Trials Network (CITN)
Martin A. Cheever, MD  Fred Hutchinson Cancer Research Center
Maryland Ballroom

Session 201: Richard V. Smalley, MD Memorial Lectureship

8:35 8:40 a.m. Introduction
Lisa H. Butterfield, PhD – University of Pittsburgh
Maryland Ballroom
8:40 9:20 a.m. Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
9:20 9:25 a.m. Q&A and Closing Remarks
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

Session 202: Mechanisms of Acquired Resistance to Immunotherapies

Co-Chairs:

Katerina Politi, PhD Yale School of Medicine
Antoni Ribas, MD, PhD University of California, Los Angeles

9:25 9:30 a.m. Introduction
Katerina Politi, PhD – Yale School of Medicine

Maryland Ballroom
9:30 9:55 a.m. Acquired Resistance Checkpoint Inhibitors in Lung Cancer
Katerina Politi, PhD – Yale School of Medicine
9:55 10:20 a.m. Acquired Resistance to PD-1 Blockade in Melanoma
Antoni Ribas, MD, PhD – University of California, Los Angeles
10:20 10:45 a.m. Break Prince George Exhibition Hall DE
10:45 11:10 a.m. Acquired Resistance in Melanoma
Annette Paschen, MD – University Hospital Essen
Maryland Ballroom
11:10 11:25 a.m. Single Cell RNA Sequencing Reveals Mechanisms of Merkel Cell Carcinoma Escape from Intense Pressure of T Cell Immunotherapy
Kelly Paulson, MD, PhD Fred Hutchinson Cancer Research Center
11:25 11:40 a.m. A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance
Jason Williams, BS University of Chicago
11:40 11:55 a.m. Functional Correlation of Increased Tumor Intrinsic Glycolytic Activity with Resistance to Adoptive T Cell Therapy
Weiyi Peng, MD, PhD The University of Texas MD Anderson Cancer Center
11:55 a.m.  Noon Closing Remarks
Antoni Ribas, MD, PhD – University of California, Los Angeles

Session 203: Late Breaking Abstract Session II

12 12:15 p.m. Preliminary antitumor and immunomodulatory activity of BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, in combination with nivolumab in patients with advanced cancers
Jason J. Luke, MD – University of Chicago Medical Center
Maryland Ballroom
12:15 12:30 p.m. The transcription factor Myb enhances CD8+ T cell stemness and polyfunctionality to promote curative antitumor immunity
Sanjivan Gautam, PhD – National Cancer Institute
12:30 2 p.m. Lunch & Poster Viewing/Presentations Prince George Exhibition Hall DE
12:45 1:45 p.m. Oral Poster Presentations Back of Prince George Exhibition Hall DE

Concurrent Session 204: Presidential Session

2 – 2:05 p.m.  Introduction
Lisa H. Butterfield, PhD – University of Pittsburgh
Maryland Ballroom C
2:05 – 2:20 p.m.  Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors
Vinod Balachandran, MD Memorial Sloan Kettering Cancer Center
2:20 – 2:35 p.m. Neoadjuvant Nivolumab Versus Combination Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Patients with Resectable Stage III and Oligometastatic Stage IV Melanoma: Preliminary Findings
Sangeetha M. Reddy, MD, MSc The University of Texas MD Anderson Cancer Center
2:35 – 2:45 p.m. Expert Discussant
Charles Drake, MD, PhD – Columbia University Medical Center
2:45 – 3 p.m. Cross-Dressed Dendritic Cells Drive Anti-Tumor Immunity
Brendan MacNabb, BS The University of Chicago
3 – 3:15 p.m. Metabolic Adaptations Establish Immunotherapy Resistance in Melanoma
Ashvin R. Jaiswal, DPharm, MS, PhD UT MD Anderson Cancer Center
3:15 – 3:25 p.m. Expert Discussant
Susan M. Kaech, PhD Yale University

Concurrent Session 205: Tumor Immunology 101 (Physician/Nurse/Pharmacy Track)

Co-Chairs:

Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

2:05 p.m. Introduction
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Cherry Blossom Ballroom
2:05 2:30 p.m. Immunology 101 for the Non-Immunologist
Yvonne Saenger, MD – Columbia University Medical Center
2:30 2:55 p.m. Basic Principles of Tumor Immunotherapy
Michael K. Wong, MD, PhD, FRCPC – MD Anderson Cancer Center
2:55 3:20 p.m. Drug Classification & MOAs
Lisa M. Cordes, PharmD, BCACP, BCOP – National Cancer Institute
3:20 3:25 p.m. Closing Remarks
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
3:25 3:40 p.m. Break Cherry Blossom Foyer

Concurrent Session 206: Economics of Immunotherapies and Immunotherapy Combinations

Co-Chairs:

Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
Bruce Levine, PhD – Abramson Cancer Center

3:25 3:27 p.m. Introduction
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Maryland Ballroom C
3:27 3:42 p.m. Report on Economics of Checkpoint Inhibitors in Melanoma
Ahmad Tarhini, MD, PhD – University of Pittsburgh Cancer Institute
3:42 3:57 p.m. Report on Economics of Adoptive Cell Therapy
Richard Maziarz, MD – Oregon Health & Science University
3:57 4 p.m. Q&A and Closing Remarks
4:15 p.m. Plenary Session Break Maryland Foyer

Concurrent Session 207: Clinical Trials: Novel Combinations

Co-Chairs:
3:30 – 3:45 p.m. A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC)
Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center
Maryland Ballroom A
3:45 – 4 p.m. ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC)
Leena Gandhi, MD, PhD – NYU Langone Medical Center
4 – 4:15 p.m. OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results
Anthony J. Olszanski, MD – Fox Chase Cancer Center
4:15 4:30 p.m. Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab
Jose Saro, MD – Roche Innovation Center Zurich
4:30 - 4:45 p.m. First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors
Zev Wainberg, MD – UCLA School of Medicine
4:45 – 5 p.m. TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T Cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patients
Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center
5 – 5:15 p.m. Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/Metastatic Solid Tumors
Adi Diab, MD – The University of Texas MD Anderson Cancer Center
5:15 – 5:30 p.m. DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
Douglas McNeel, MD, PhD – University of Wisconsin
5:30 – 5:45 p.m. A Dendritic Cell Targeting NY-ESO-1 Vaccine Significantly Augments Early and Durable Immune Responses in Melanoma Patients Pretreated with Human Flt-3 Ligand
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
5:45 – 6 p.m. Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation
Jason Luke, MD – University of Chicago Medical Center

Concurrent Session 208: Clinical Management (Physician/Nurse/Pharmacy Track)

Co-Chairs: 

Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

3:40 3:45 p.m. Introduction
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Cherry Blossom Ballroom
3:45 4:15 p.m. General Concepts of Toxicity Management
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
4:15 4:35 p.m. Pharmacological Management of irAEs
Nathan Dahl, PharmD, R.Ph, BCOP – Clovis Oncology
4:35 5 p.m. Panel Discussion: Management of Complex Adverse Events
Moderator: Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute

Panel: Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Nathan Dahl, PharmD – Mayo Clinic
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
5 5:15 p.m. Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool
Krista Marcello, BA – Clinical Care Options, LLC
5:15 5:30 p.m. Audience Question & Answer
Moderator: Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital

Concurrent Session 209: Emerging Models & Imaging

Co-Chairs:

Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health

4:15 4:20 p.m. Introduction
Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health
Maryland Ballroom C
4:20 4:40 p.m. Imaging Immunity - Developing a Spatiotemporal Understanding of Host Defense and Tumor Immunity
Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health
4:40 5 p.m. Molecular Imaging of Checkpoint Blockade
Sridhar Nimmagadda, PhD – Johns Hopkins University
5:20 p.m. Multiplex Three-Dimensional Optical Mapping of Tumor Immune Microenvironment
Steve Seung-Young Lee, PhD – University of Chicago
5:20 5:35 p.m. Combining Immunophenomics with a Gene Expression Panel for Improved Prostate Cancer Recurrence Prediction
Nathalie Harder, PhD – Definiens AG
5:35 5:40 p.m. Closing Remarks

Award Ceremony

6:00 – 6:30 p.m. Award Ceremony
Lisa H. Butterfield, PhD – University of Pittsburgh
Maryland Ballroom C
6:30 8 p.m. Evening Poster Reception & Viewing Prince George Exhibition Hall DE
8:30 11:30 p.m. The CheckPoints Party Maryland Ballroom

Sunday, Nov. 12

7 8 a.m. Breakfast Cherry Blossom Foyer
7 10 a.m. Registration Cherry Blossom Foyer
8:05 a.m. Organizer Welcome
Marcela V. Maus, MD, PhD Massachusetts General Hospital 
Cherry Blossom Ballroom

Session 300: Genetically Modified Cell Therapy

SITC is pleased to offer a live streaming webcast of Session 300: Genetically Modified Cell Therapy. Click here for more information and to register for the webcast.

Organized in collaboration with the American Society for Blood and Marrow Transplantation (ASBMT)

Co-Chairs:

Marcela V. Maus, MD, PhD – Massachusetts General Hospital 
Carl H. June, MD – University of Pennsylvania
Helen E. Heslop, MD – Baylor College of Medicine

8:05 8:30 a.m. CAR T Cells Smarter Targeting and Smarter Targets
Martin Pule, PhD – University College London
Cherry Blossom Ballroom
8:30 8:55 a.m. Updates in CAR T cells
Crystal L. Mackall, MD – Stanford University
8:55 9:20 a.m. Genetically Modified T Cells for Solid Tumors
Stephen Gottschalk, MD – St. Jude Children's Research Hospital
9:20 9:45 a.m. Late-Breaking: CD19 CAR Enter the Mainstream
Jennifer Brogdon – Novartis Institute of Biomedical Research
9:45 10 a.m. Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cells
Angela Boroughs, BS – Massachusetts General Hospital, Harvard University
10 – 10:15 a.m. Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T Cells
Margot Pont, PhD – Fred Hutchinson Cancer Research Center

Session 301: Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?

SITC is pleased to offer a live streaming webcast of Session 301: Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy? Click here for more information and to register for the webcast.

Organized in collaboration with Stand Up To Cancer

Co-Chairs:
Howard Kaufman, MD, FACSReplimune Group, Inc.
Herbert Levine, PhDRice University

10:30 – 10:35 a.m.

Welcome and Introductions
Howard Kaufman, MD, FACS – Replimune Group, Inc.

Cherry Blossom Ballroom

10:35 – 10:55 a.m. Overview of the Immunotherapy Field
Francesco M. Marincola, MD – AbbVie Inc.
10:55 – 11:15 a.m. Integrating Multiple Dimensions of Genomic Data as Immunotherapy Predictive Biomarkers
Thomas F. Gajewski, MD, PhD University of Chicago
11:15 – 11:35 a.m. Challenges in Clinical Development
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
11:35 – 11:55 a.m. Systems of Biology Modeling of the Immune System
Doron Levy, PhD – University of Maryland
11:55 – 12:15 p.m. T Cell Repertoire
Curtis Callan, PhD – Princeton University
12:15 – 12:35 p.m. Modeling the Fitness Costs of Neoantigens
Benjamin Greenbaum, PhD – Tisch Cancer Institute
12:35 – 1 p.m. Panel Discussion
Moderators:
Howard Kaufman, MD, FACS – Replimune Group, Inc.
Herbert Levine, PhD – Rice University